Table 2.

Motivations that influenced the decision of physicians to prescribe liraglutide—FAS

Motivation	n/total analyzed (%)
Improvement of glycemic control	2552/3145 (81.1)
Reduction of hypoglycemic episodes	290/3144 (9.2)
Improvement of weight control	2113/3145 (67.2)
Potential beneficial effect on beta-cell function	915/3145 (29.1)
Improvement of blood pressure	284/3143 (9.0)
Adverse effect of current treatment	324/3145 (10.3)
Patient dissatisfaction with current treatment	578/3144 (18.4)
Trying a new treatment	578/3144 (18.4)
Potential beneficial effect of other properties of GLP-1	956/3144 (30.4)

Due to missing data, the % value relates to the number of patients analyzed within the FAS population for that particular motivation and not the total FAS population. Physicians may have had more than one motivation for prescribing liraglutide

FAS full analysis set, GLP-1 glucagon-like peptide-1, n number for subset